-
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners July 12, 2026 11:18 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data…
-
Basecamp Research brings EDEN’s antibiotic and vaccine design models to Claude Science
Scientists can now design potent antibiotics and rapidly prioritise vaccine targets through Claude Science, thanks to integration with Basecamp Research’s EDEN models. LONDON and CAMBRIDGE, Mass., June 30, 2026 /PRNewswire/ — Basecamp Research today announced that its antibiotic design and vaccine target prediction EDEN models are now available through Claude, including Claude Science, Anthropic’s AI…
-
Dyne Therapeutics Appoints Barry Greene to Board of Directors
June 22, 2026 16:10 ET | Source: Dyne Therapeutics, Inc. WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Barry Greene to its Board of Directors. Mr. Greene brings more…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
